Thus, while the pivotal role of TET2 mutations is underlined by their high frequency in myeloid disorders, including AML, the lack of molecular lesions in the homologous TET1/TET3 genes is probably explicable with a distinct tissue-specific expression and differences in the specific metabolic consequences derived from their imbalance [26]. The gene discussed is TET3; the disease is acute myeloid leukemia.